<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937349</url>
  </required_header>
  <id_info>
    <org_study_id>Calcification</org_study_id>
    <nct_id>NCT03937349</nct_id>
  </id_info>
  <brief_title>Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients</brief_title>
  <official_title>Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Petersburg State University, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Petersburg State University, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study aimed to evaluate change of cardiovascular calcification
      after parathyroidectomy in patients with end-stage renal disease on dialysis compared with
      control group on conservative treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coronary artery calcium score measured with CT</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vascular calcification score measured with semi-quantitative (Kauppila) test</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in heart valve calcium score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intact parathyroid hormone (iPTH) level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum calcium level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum phosphate level</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alkaline phosphatase</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (cardiovascular events, death, fractures, emergency hospital admissions) during the follow-up period</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>Chronic Kidney Disease Mineral and Bone Disorder</condition>
  <condition>Vascular Calcification</condition>
  <condition>Dialysis</condition>
  <arm_group>
    <arm_group_label>sPTx group</arm_group_label>
    <description>Patients underwent subtotal parathyroidectomy due to severe secondary hyperparathyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPTx+AT group</arm_group_label>
    <description>Patients underwent total parathyroidectomy with immediate autotransplantation of parathyroid tissue due to severe secondary hyperparathyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients with severe SHPT on conservative treatment (calcimimetics, active vitamin D analogues, phosphate-binders) who are likely to undergo surgery in a period of 12 months</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving long-term dialysis treatment, met the criteria for parathyroidectomy due
        to severe SHPT
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years

          2. ESRD patients receiving long-term hemodialysis or peritoneal dialysis treatment

          3. Severe secondary hyperparathyroidism defined as iPTH level &gt; 800 pg/ml, followed with
             hypercalcemia and/or hyperphosphatemia; with presence of one or more nodular or
             diffuse parathyroid hyperplasia confirmed with CT

        Exclusion Criteria:

        1. Primary hyperparathyroidosis as a cause of ESRD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterina Parshina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Petersburg State University, Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ekaterina Parshina, MD</last_name>
    <phone>+7(812)676-25-25</phone>
    <email>pannn@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint-Petersburg State University, Clinic of advanced medical technologies n.a. N.I.Pirogov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Parshina, MD</last_name>
      <phone>+7(812)676-25-21</phone>
      <email>pannn@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Petersburg State University, Russia</investigator_affiliation>
    <investigator_full_name>Ekaterina Parshina</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

